Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Gyre Therapeutics Inc (GYRE)

53 + Investors. Track Smart Money conviction in GYRE. See who's accumulating, reducing, or initiating positions.

Fetching live quote...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +10
Streak
1Q ▲
Buyers last Q
65%

Smart Money Signals — GYRE

Based on 53 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added GYRE than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
53 hedge funds hold GYRE right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +20% more funds vs a year ago

fund count last 6Q
+9 new funds entered over the past year (+20% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟢

More buyers than sellers — 65% buying

30 buying16 selling
Last quarter: 30 funds were net buyers (15 opened a brand new position + 15 added to an existing one). Only 16 were sellers (11 trimmed + 5 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+12 vs last Q)

new funds entering per quarter
Funds opening a new GYRE position: 9 → 10 → 3 → 15. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔄

Mostly new holders — 38% entered in last year

23% conviction (2yr+) 40% medium 38% new
Only 12 funds (23%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
➡️

Steady discovery — ~15 new funds/quarter

10 → 9 → 10 → 3 → 15 new funds/Q
New funds entering each quarter: 9 → 10 → 3 → 15. Consistent flow of new institutional buyers without clear acceleration or slowdown.
📊

Mixed cohorts — 19% veterans, 45% new entrants

19% veterans 36% 1-2yr 45% new
Of 53 current holders: 10 (19%) held 2+ years, 19 held 1–2 years, 24 (45%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

Strong quality — 36% AUM from major funds

36% from top-100 AUM funds
22 of 53 holders rank in the top 100 by AUM, accounting for 36% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.1
out of 10
Moderate Exit Risk
Exit risk score 4.1/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — GYRE

In 2026 Q1, 30 hedge funds were net buyers of GYRE (15 opened a new position, 15 added to an existing one), while 16 reduced or exited (11 trimmed, 5 sold completely) — a 65% buyer ratio, indicating clear institutional accumulation. 36% of total institutional value in GYRE is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +10 funds (more new holders than closures). Total institutional holders: 53.

Hedge Fund Ownership: GYRE

How many hedge funds hold GYRE — quarterly history vs. share price
Quarterly hedge fund ownership of GYRE vs. share price

Market Analysis: GYRE

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: GYRE

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Gyre Therapeutics Inc (GYRE) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much GYRE has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 78d ago
GYRE
-12.8%
XLV
+2.8%

GYRE outperformed XLV by -15.6% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 33d ago
GYRE
-7.2%
XLV
+3.9%

Since the filing became public, GYRE outperformed XLV by -11.1% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

10 top-rated funds 0 high-conviction
Consensus
4.5
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: GYRE
53 + Investors

Track Smart Money conviction in GYRE. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 53 43 23.26%
13F Shares 3M 3M 1.12%
Total Value $24M $24M -0.15%
New Positions 15 3 +12
Increased Positions 15 23 -8
Closed Positions 5 5 -
Reduced Positions 11 8 +3
Total Calls 0 0 -
Total Puts 0 1 -100.0%
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: GYRE

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

53 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in GYRE. Verified SEC 13F-HR filings.

QUARTER:
Top 25 GYRE holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 SBI Securities Co., Ltd. 0.03% 170,837 $1.2M
2 Tower Research Capital LLC (TRC) 0.00% 5,763 $40K
3 Brevan Howard Capital Management LP 0.00% 13,808 $96K
4 Activest Wealth Management 0.00% 533 $4K
5 Strs Ohio 0.00% 21,100 $147K
6 Vanguard Fiduciary Trust Co 0.00% 137,682 $960K
7 Vanguard Capital Management LLC 0.00% 984,204 $6.9M
8 Ameritas Investment Partners, Inc. 0.00% 683 $5K
9 Police & Firemen's Retirement System of New Jersey 0.00% 2,097 $15K
10 BlackRock, Inc. 0.00% 758,630 $5.3M
11 Rhumbline Advisers 0.00% 13,116 $91K
12 GoalVest Advisory LLC 0.00% 50
13 Goldman Sachs Group Inc 0.00% 73,122 $510K
14 MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 0.00% 5,617 $39K
15 Alliancebernstein L.P. 0.00% 21,830 $154K
16 GAMMA Investing LLC 0.00% 82
17 New York State Common Retirement Fund 0.00% 2,700 $19K
18 Vanguard Portfolio Management LLC 0.00% 69,814 $487K
19 Deutsche Bank Ag\ 0.00% 10,613 $74K
20 UBS Group AG 0.00% 21,087 $147K
21 Allworth Financial LP 0.00% 721 $5K
22 Essential Partners LLC 0.00% 4
23 BNP Paribas Financial Markets 0.00% 2,571 $18K
24 Russell Investments Group, Ltd. 0.00% 1,124 $8K
25 Sterling Capital Management LLC 0.00% 59
Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Gyre Therapeutics Inc (GYRE)

What does the Smart Money Trend signal show for GYRE?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added GYRE than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for GYRE?

More buyers than sellers — 65% buying: Last quarter: 30 funds were net buyers (15 opened a brand new position + 15 added to an existing one). Only 16 were sellers (11 trimmed + 5 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for GYRE holders?

Strong quality — 36% AUM from major funds: 22 of 53 holders rank in the top 100 by AUM, accounting for 36% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held GYRE?

Mostly new holders — 38% entered in last year: Only 12 funds (23%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Gyre Therapeutics Inc (GYRE) following the 2026 Q1 hedge fund 13F filings?

As of today, GYRE has moved -7.2% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of -11.1%. Since the quarter end (March 31, 2026), GYRE has gained -12.8% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →